Figure 2
Dot blotting analysis for binding site confirmation. Dot blotting was performed to define the geometric orientations of the selected aptamers.
(a) LCN2 (74.2 pmol) with 9 selected aptamers (LCN2_Apta1 to LCN2_Apta9, 742 pmol) and controls (C1 to C4) were dotted onto the Hybond-P PVDF membrane. After incubation with the HRP-conjugated anti-LCN2 polyclonal antibody, an assay image was taken using an ECL assay protocol. The plotted signal intensities were calculated using ImageJ software and normalized to C2 (LCN2 74.2 pmol). The schematic epitope binding of two aptamers (LCN2_apta2 and LCN2_apta4) is illustrated in (b). All parts of this figure were drawn by the authors K-A. L. and J-Y. A.
